spacer
home > ebr > Winter 2013
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2013

   
Text
PDF
bullet
BioResearch and Innovation
Cell Based Therapies

Nobels and Stem Cells


The work of Sir John Gurdon and Shinya Yamanaka was recently awarded the Nobel Prize in Physiology or Medicine. Their groundbreaking work has led Dean Griffiths at Cambridge Consultants to investigate how a major discovery can start from a minor question.
 
view
download pdf
Single-use Bioreactors

Rapid Reaction


Traditional stainless steel reactors are being overtaken by single-use bioreactors. Lee Madrid at EMD Millipore Corporation and Aurore Poles-Lahille at Millipore SAS outline the advantages that this new technology can bring.
 
view
download pdf
bullet
Discovery Technology
Cloud Computing

Up, Up and Away


Inefficient data processing often stifles innovation in research and development. Richard Heitmann at Aspera discusses the vast possibilities to be gained in new medical advancements when modern technology is used to its full potential.
 
view
download pdf
BioDevelopment
Sharing Data

Personal Medicine


In order to provide more bespoke therapeutics for cancer treatment, the industry needs to make a more conscious effort to collaborate and share patient data, says Markus Warmuth at H3 Biomedicine.
 
view
download pdf
bullet
Drug Discovery
Stem Cell Technology

Treatment from Within


Distinguishing the correct cell types in liver cell transplantation is a vital factor that contributes substantially to the success of this therapy. Eric Halioua and Etienne Marc Sokal atPromethera Biosciences explore the advantages that intrahepatic cells have over other sources.
 
view
download pdf
Differentiated Cells

iPS Power

The world of patient therapeutics can be drastically transformed through the use of in vitro differentiated cells that are derived from human induced pluripotent stem cells, Felix Haniel of Axiogenesis AG explains.
 
view
download pdf
Safety Profile

A Marked Difference


Biomarkers are an invaluable tool in drug discovery and development. Federica Crivellente and Elena Vicentini at Aptuit suggest that the use of high throughput technologies can help to generate high quality data in a more efficient and cost-effective way.
 
view
download pdf
Stem Cells in Drug Discovery

Patient in a Dish


Roberto Iacone at Roche and Blake Anson at Celluar Dynamics International examine how using improved induced pluripotent stem cell models will result in more effective medicines and help to overcome some of the challenges in this field.
 
view
download pdf
bullet
BioRegional
Biosimilars: Asian Markets

Biotech in China


James C Greenwood
at Biotechnology Industry Organization assesses the growth of the Chinese biotech industry and how investment into new products could secure their position in the drug development and manufacturing market.
 
view
download pdf
bullet
DEVELOPMENT AND PRODUCTION
Cell Line Development

Database Power


When trying to identify new cell lines, progress can be stifled by the data management process. If a more highly developed system were to be implemented, development timelines would decrease rapidly, as Eliot Randle at IDBS demonstrates.
 
view
download pdf
Diabetes Therapeutics

Crackling the Code


A promising alternative for the treatment of type 1 diabetes has been discovered. Peter Hosking at Living Cell Technologies illustrates how using encapsulated porcine insulin-producing cells significantly reduces the number of hypoglycaemic events.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Saneca Pharma strengthens senior team

Slovakia-based CDMO adds senior talent to its team to position the company for continued growth
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

Industry Events

Outsourcing in Clinical Trials Medical Devices 2017

27-28 June 2017, Santa Clara, CA

OCT Medical Devices moved to Irvine, California for the first year in 2016, and we are pleased to say it proved a resounding success. As the only event to cater for the Southern California Medical device hub in Irvine, it brought together a variety of medical device companies of all sizes, including Medtronic, Edwards Lifesciences, Onciomed, Inc and St Jude Medical.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement